The U.S. Food and Drug Administration (FDA) has approved Innoviva Inc.’s (NASDAQ: INVA) treatment of asthma and for patients with chronic obstructive pulmonary disease (COPD), the company announced, giving shares a boost early Thursday.
Specifically, the FDA has approved Innoviva’s Trelegy Ellipta for the treatment of asthma patients aged 18 years and older, adding to its current license for use in patients with COPD.
The approval means Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD and is the only single inhaler triple therapy available for patients in a convenient once-daily inhalation in the United States.
This approval was based on a supplemental New Drug Application (sNDA) that included data from the Captain study, showing that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist (ICS/LABA), the additional bronchodilation provided by Trelegy demonstrated significant improvements in lung function.
In a sense, Trelegy’s approval for the maintenance treatment of asthma in patients 18 and older yields a new paradigm for managing about 30% of adult asthma patients who still experience symptoms despite being adherent to ICS/LABA combination therapy.
Management noted that Trelegy was approved in the United States in 2017 as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains the market leader. However, this approval in asthma is another significant step in the treatment of respiratory diseases.
Innoviva stock traded up 4% early Thursday at $12.19, in a 52-week range of $7.58 to $15.62. The consensus price target is $8.00.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
